Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2282512A

Next Previous
Drug Profile

GSK 2282512A

Alternative Names: FLU Q-QIV; FluLaval Quadrivalent; Flulaval Tetra; FLuZactal Tetra; GSK-2282512A; GSK-2833489A; Quadrivalent seasonal influenza vaccine - GlaxoSmithKline

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline Biologicals
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 21 Nov 2016 Registered for Influenza virus infections (Prevention, In infants, In children) in USA (IM)
  • 02 Feb 2016 Registered for Influenza virus infections (Prevention, In infants, In children, In adolescents, In adults) in Mexico (IM) before February 2016
  • 02 Feb 2016 GlaxoSmithKline files sBLA for inclusion of infants and children aged 6 months to 35 months for Influenza virus infections (Prevention) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top